Post-earnings recap
Reported
Tue, Aug 8, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Nektar Therapeutics reported a larger-than-expected loss per share, which contributed to a 3.01% decline in stock price following the earnings announcement. The lack of revenue figures and guidance may have raised concerns among investors about the company's future performance. Overall, the results indicate ongoing challenges for the company in meeting market expectations.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.39 | N/A | -16.58% |
| Revenue | N/A | N/A | N/A |
Management expressed concern over the current financial performance. They did not provide detailed guidance for future quarters.
Management did not provide specific insights into revenue expectations.
The company acknowledged challenges in meeting market expectations.